



Dr. Joachim Müller

Leitende(r) Arzt/Ärztin
Radiologie und Nuklearmedizin · Dept. IV

Kontakt

Dr. Joachim Müller
Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T 071 494 2249
joachim.mueller@kssg.ch

Bereiche

Radiologie und Nuklearmedizin

Funktion

Leitende(r) Arzt/Ärztin

Forschungsgebiet

PET-CT

Mitgliedschaften

SGNM, SGR, DGN

Publikationen (26)

Neff D, Padberg Sgier B, Dietze H, Müller J, Früh M. Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports. *Case Rep Oncol* 2022; 15:1001-1008.

Grünig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger I, Müller J. Focal unspecific bone uptake on [F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. *Eur J Nucl Med Mol Imaging* 2021; 48:4483-4494.

Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. *Cancer Immunol Immunother* 2020; 70:563-568.

Müller J, Früh M, Siano M. Radiation dosimetry of ¹⁸F-AzaFol: A first inhuman use of a folate receptor PET tracer. *EJNMMI Research* 2020; 10

Gnesin S, Prior J, Treyer V, Kaufmann P, Ametamey S, Schibli R, Müller C, Choschzick M, Früh M, Siano M, Meisel A, Burger I, Müller J, Schaefer N. Radiation dosimetry of F-AzaFol: A first in-human use of a folate receptor PET tracer. *EJNMMI Res* 2020; 10:32.

Isensee G, Péporté A, Müller J, Schmid S, Gillessen Sommer S, Omlin A. Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?. *Clin Genitourin Cancer* 2018; 16:349-354.

Glatzer M, Rittmeyer A, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora P. Treatment of limited disease small cell lung cancer: the multidisciplinary team. *Eur Respir J*. 2017; 50

Fehr M, Müller J, Knitel M, Fornaro J, Horber D, Koeberle D, Cerny T, Gueller U. Early Postoperative FDG-PET-CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients. *Clin Colorectal Cancer* 2017

Putora P, Szentesi K, Glatzer M, Rodriguez R, Müller J, Baty F, Früh M. SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. *Oncol Res Treat* 2016; 39:681-686.

Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. *JAAD Case Rep* 2016; 2:415-417.

Glatzer M, Putora P, Müller J, Minervini F, Plasswilm L (2016). Case report: radio-supersensitive oligometastatic lung cancer.

Markus A, Ray A, Bolla D, Müller J, Diener P, Wendler T, Hornung R. Sentinel lymph node biopsy in endometrial and cervical cancers using freehand SPECT - first experiences. *Gynecol Surg* 2016; 13:499-506.

Müller J, Putora P, Schneider T, Zeisel C, Brutsche M, Bartz-Batliner M, Markus A, Kick J. Handheld single photon emission computed tomography (handheld SPECT) navigated video-assisted thoracoscopic surgery of computer tomography-guided radioactively marked pulmonary lesions. *Interact Cardiovasc Thorac Surg* 2016; 23:345-350.

Marsico J, Rodriguez R, Müller J, Jörger M. Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis. *J Cancer Res Ther* 2015; 11:647.

Niederer-Wuest S, Stöckli S, Haile S, Müller J, Oettli R, Clerici T, Bilz S, Brändle M, Förbs D, Jochum W, Broglio D, Däppen M. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. *Surgery* 2015; 157:119-25.

Schmid S, Öhlschlegel C, Nagel W, Zeisel C, Müller J, Rothermundt C. Pulmonary embolism in a patient with primary renal synovial sarcoma: the important differential diagnosis of tumor embolism and its therapeutic implications. *Case Rep Oncol* 2013; 6:331-8.

Putora P, Früh M, Müller J. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. *Respirology* 2013; 18:734-5.

Putora P, Müller J, Borovicka J, Plasswilm L, Schmidt F. Relevance of incidental colorectal FDG-PET/CT-enhanced lesions. *Onkologie* 2013; 36:200-4.

Horstkemper R, Brügge D, Müller J, Mock B, Plasswilm L (2012). Post Irradiation Sign of Progress in Anaplastic Ependymoma – A Case Report.

Putora P, Horstkemper R, Müller J, Plasswilm L (2012). Radiotherapy with 3Gy for Inflammation due to Heterotopic Ossifications.

Brügge D, Putora P, Engeler D, Müller J, Schmidt F, Plasswilm L (2011). SPECT-CT, Cholin-PET-CT, MRI and CT for Diagnosis of Prostate Cancer in the Prostate Bed, Regional Lymph Node and Bone Lesion.

Putora P, Brügge D, Schmidt F, Engeler D, Müller J, Plasswilm L (2011). Postoperative Prostate Radiotherapy: Did we need Bone Scans?.

Heinzerling L, Anliker M, Müller J, Schlaeppi M, von Moos R. Sarcoidosis induced by interferon- α in melanoma patients: incidence, clinical manifestations, and management strategies. *J Immunother* 2010; 33:834-9.

Putora P, Schmidt F, Stolz A, Müller J, Plasswilm L (2010). The Necessity for Workup of Incidental Colon FDG Lesions in PET-CT During Staging.

Schmidt F, Cathomas R, Stallmach T, Putora P, Müller J. Have you ever heard of hibernoma? A rare but important pitfall in FDG-PET/CT. *Nuklearmedizin* 2010; 49:N71-3.

Fehr T, Rickli H, Müller J, Wüthrich R, Ammann P. Kidney at risk: 11-year course of renal artery stenosis. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2003; 18:443-4.

Projekte (3)

Biodistribution, Tumor Detektion und Dosimetrie von [18F]-AzaFol als Positronen Emissions Tomographie (PET) Tracer für die Bildgebung von Folat Rezeptor Positivem Krebs

Klinische Forschung - 23.11.2015 - 23.11.2018

Automatisch geschlossen

Thorakoskopische Handheld-SPECT gesteuerte Ektomie von radioaktiv-markierten pulmonalen Rundherden

Klinische Forschung - 01.11.2013 - 31.10.2015

Automatisch geschlossen

Molecular and mutational profiling in Papillary Thyroid Carcinoma with special emphasis on the influence of BRAFV600E Mutation on Tumor Stage, Outcome and nuclear imaging

Klinische Forschung - 21.01.2011 - 30.12.2013

Abgeschlossen